Aldeyra Therapeutics

$12.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.50 (+4.24%) Today

+$0.15 (+1.22%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ALDX and other stocks, options, and ETFs commission-free!

About ALDX

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA. The listed name for ALDX is Aldeyra Therapeutics, Inc. Common Stock.

CEO

Todd C. Brady

Employees

Headquarters

Lexington, Massachusetts

Founded

2004

Market Cap

584.99M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

2.47M

High Today

$12.48

Low Today

$11.91

Open Price

$12.36

Volume

1.23M

52 Week High

$14.62

52 Week Low

$1.48

Collections

ALDX News

Benzinga17h

Notable Insider Buys Of The Past Week: Affirm, HEICO, Vector Group, Biotechs And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Insiders have been taking advantage of secondary

Analyst Ratings

100%

of 8 ratings

Buy

100%

Hold

Sell

ALDX Earnings

-$0.72

-$0.48

-$0.24

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 11, Pre-Market